Company intelligence / Profile preview

Medartis

Ownership: Private
Employees: ~949
Development stage: Commercial

Overview

Medartis offers a broad portfolio of CE-marked/FDA-cleared implant systems for bone fracture fixation in the head and extremities. Its products are widely used globally with over one million distal radius plates sold as of 2023. The company continues to innovate with new product launches and acquisitions expanding its reach in the US and Brazil. Clinical results are consistent with standard-of-care outcomes for surgical osteosynthesis.

Therapeutic areas: OtherRheumatology
Modalities: Device (specifically titanium implants and surgical instruments for osteosynthesis)
Industry: Implantable Medical Devices

Beyond the preview

Go deeper on Medartis.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Medartis.

Explore the full profile